期刊文献+

胃癌恶性腹水来源类器官培养与药物敏感性筛查 被引量:2

Gastric cancer malignant ascites derived organoid culture and drug sensitivity screening
下载PDF
导出
摘要 目的建立胃癌恶性腹水来源类器官模型,并将该模型用于化疗药物筛查。方法收集4例胃癌患者的腹水,离心处理后与基质胶混合种板,然后添加含有生长因子的培养基进行类器官培养。采用苏木精-伊红染色和免疫组织化学染色法对胃癌腹水来源类器官和原始恶性腹水肿瘤细胞进行病理形态学及相关免疫标志物分析。通过对2种化疗药物顺铂和氟尿嘧啶的敏感性筛查,评估胃癌恶性腹水来源类器官用于药物筛选的适用性。结果成功培养3例胃癌恶性腹水来源类器官,类器官的形态和生长特征存在个体差异性,所有类器官均可稳定传代、冻存与复苏。胃癌恶性腹水来源类器官保留了相应恶性腹水肿瘤细胞的组织结构特征,相关免疫标志物表达基本保持一致。3例类器官对2种化疗药物表现出不同的药物敏感性,对氟尿嘧啶均耐药,对顺铂的耐药存在个体差异。结论本研究成功建立胃癌恶性腹水来源类器官模型,该模型很好地保持了胃癌恶性腹水原始肿瘤细胞的病理学特征。类器官对2种化疗药物的反应初步证实其作为体外药物筛选模型的可行性。 Objective The purpose of this study was to establish a gastric cancer-derived organoid model from malignant ascites and to use this model for chemotherapeutic drug screening.Method The ascites of 4 patients with gastric cancer were collected,they were mixed with Matrigel and seeded after centrifugation.The medium containing growth factors was added for organoid culture.Hematoxylin-eosin staining and immunohistochemical staining were used to analyze the pathological morphology and related immune markers of gastric cancer ascites-derived organoids and primitive malignant ascites tumor cells.The applicability of gastric cancer-derived organoids from malignant ascites for drug screening was assessed by sensitivity screening to two chemotherapeutic drugs include cisplatin and fluorouracil.Result Three cases of gastric cancer-derived organoids from malignant ascites were successfully cultured.There were individual differences in the morphology and growth characteristics of the organoids.All organoids could be stably passaged,cryopreserved,and resuscitated.The malignant ascites-derived organoids of gastric cancer retained the histological characteristics of the corresponding malignant ascites tumor cells,and the expression of related immune markers remained basically the same.The three organoids showed different drug sensitivities to the two chemotherapeutic drugs,all were resistant to fluorouracil,and there were individual differences in the resistance to cisplatin.Conclusion In this study,an organoid model derived from malignant ascites of gastric cancer was successfully established,which maintained the pathological characteristics of the original tumor cells of malignant ascites of gastric cancer well.The organoid response to two chemotherapeutic drugs preliminarily confirmed its feasibility as an in vitro drug screening model.
作者 胡蕾 陈伟 张世维 蒋菲 文璋 刘宇虹 胡臻然 曹清华 杨峥 Hu Lei;Chen Wei;Zhang Shiwei;Jiang Fei;Wen Zhang;Liu Yuhong;Hu Zhenran;Cao Qinghua;Yang Zheng(Department of Pathology,The Seventh Affiliated Hospital of Sun Yat-Sen University,Shenzhen 518000,Guangdong,China;Digestive Diseases Center,The Seventh Affiliated Hospital of Sun Yat-Sen University,Shenzhen 518000,Guangdong,China;General Surgery,The Seventh Affiliated Hospital of Sun Yai-Sen University Shenzhen 518000,Guangdong,China;Department of Pathology,The First Affiliated Hospital of Sun Yat-Sen University,Guangzhou 510080,Guangdong,China)
出处 《消化肿瘤杂志(电子版)》 2022年第1期32-41,共10页 Journal of Digestive Oncology(Electronic Version)
基金 中山大学附属第七医院博士后启动基金(ZSQYRSFPD0008) 中山大学青年教师培育项目(2021qntd37)。
关键词 胃癌恶性腹水 类器官 药物敏感性筛查 个性化医疗 Malignant ascites of gastric cancer Organoids Drug screening Personalized medicine
  • 相关文献

参考文献1

二级参考文献20

  • 1P. Wimberger,H. Gilet,A-K. Gonschior.Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Annals of Oncology . 2012
  • 2Kuniaki Shirao,Narikazu Boku,Yasuhide Yamada,Kensei Yamaguchi,Toshihiko Doi,Masahiro Goto,Junichiro Nasu,Tadamichi Denda,Yasuo Hamamoto,Atsuo Takashima,Haruhiko Fukuda,Atsushi Ohtsu,Akira Sawaki,Hogara Nishisaki,Kenji Amagai,Yasuyuki Suzuki.Randomized Phase III Study of 5-Fluorouracil Continuous Infusion vs. Sequential Methotrexate and 5-Fluorouracil Therapy in Far Advanced Gastric Cancer with Peritoneal Metastasis (JCOG0106)[J]. Japanese Journal of Clinical Oncology . 2013 (10)
  • 3Tom Waddell,Ian Chau,David Cunningham,David Gonzalez,Alicia Frances,Clare Okines,Andrew Wotherspoon,Claire Saffery,Gary Middleton,Jonathan Wadsley,David Ferry,Wasat Mansoor,Tom Crosby,Fareeda Coxon,David Smith,Justin Waters,Timothy Iveson,Stephen Falk,Sarah Slater,Clare Peckitt,Yolanda Barbachano.Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial[J].Lancet Oncology.2013(6)
  • 4Donald Richards,Darren M. Kocs,Alexander I. Spira,A. David McCollum,Sami Diab,Lanny I. Hecker,Allen Cohn,Feng Zhan,Lina Asmar.Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomized phase 2 study[J].European Journal of Cancer.2013
  • 5T. Waddell,M. Verheij,W. Allum,D. Cunningham,A. Cervantes,D. Arnold.Gastric cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up[J].European Journal of Surgical Oncology.2014(5)
  • 6Joji Kitayama,Hironori Ishigami,Hironori Yamaguchi,Hiroharu Yamashita,Shigenobu Emoto,Shoich Kaisaki,Toshiaki Watanabe.Salvage Gastrectomy After Intravenous and Intraperitoneal Paclitaxel (PTX) Administration with Oral S-1 for Peritoneal Dissemination of Advanced Gastric Cancer with Malignant Ascites[J]. Annals of Surgical Oncology . 2014 (2)
  • 7T. Yamao,Y. Shimada,K. Shirao,A. Ohtsu,N. Ikeda,I. Hyodo.Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Tria. Japanese Journal of Clinical Oncology . 2004
  • 8Lin Shen,Jin Li,Jianming Xu,Hongming Pan,Guanghai Dai,Shukui Qin,Liwei Wang,Jinwan Wang,Zhenzhou Yang,Yongqian Shu,Ruihua Xu,Lei Chen,Yunpeng Liu,Shiying Yu,Lilian Bu,Yongzhe Piao.Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)[J]. Gastric Cancer . 2015 (1)
  • 9Simon C. Blackburn,Michael P. Stanton.Anatomy and physiology of the peritoneum[J]. Seminars in Pediatric Surgery . 2014 (6)
  • 10Nian Fang,Hui-Qing Zhang,Bo He,Mei Xie,Shan Lu,Yi-Ye Wan,Nong-Rong Wang.Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites[J]. Tumor Biology . 2014 (4)

共引文献22

同被引文献4

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部